The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Exploring ABBV-400 in second-line colorectal cancer treatment
Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines novel studies using ABBV-400, an antibody-drug conjugate targeting MET, in a second-line setting for colorectal cancer. Following promising results from a proof-of-concept study in refractory patients, this trial (NCT06107413) investigates ABBV-400 in combination with VEGF inhibitors and 5-FU. The study aims to establish safety, dosing schedules, and efficacy compared to standard-of-care bevacizumab plus FOLFIRI. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
